任天堂
肌成纤维细胞
波形蛋白
可药性
癌症研究
上皮-间质转换
纤维化
SMAD公司
受体
成纤维细胞
药理学
博莱霉素
肺纤维化
化学
特发性肺纤维化
体外
医学
肺
免疫学
过渡(遗传学)
病理
生物化学
免疫组织化学
内科学
基因
化疗
作者
Mengjiao Hao,Zhuoji Guan,Zhikang Zhang,Hongwu Ai,Peng Xing,Huihao Zhou,Jing Xu,Qiong Gu
标识
DOI:10.1016/j.ymthe.2023.08.017
摘要
Pirfenidone and nintedanib are only anti-pulmonary fibrosis (PF) drugs approved by the FDA. However, they are not target specific, and unable to modify the disease status. Therefore, it is still desirable to discover more effective agents against PF. Vimentin (VIM) plays key roles in tissue regeneration and wound healing, but its molecular mechanism remains unknown. In this work, we demonstrated that atractylodinol (ATD) significantly inhibits TGF-β1-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transition in vitro. ATD also reduces bleomycin-induced lung injury and fibrosis in mice models. Mechanistically, ATD inhibited TGF-β receptor I recycling by binding to VIM (KD = 454 nM) and inducing the formation of filamentous aggregates. In conclusion, we proved that ATD (derived from Atractylodes lancea) modified PF by targeting VIM and inhibiting the TGF-β/Smad signaling pathway. Therefore, VIM is a druggable target and ATD is a proper drug candidate against PF. We prove a novel VIM function that TGF-β receptor I recycling. These findings paved the way to develop new targeted therapeutics against PF.
科研通智能强力驱动
Strongly Powered by AbleSci AI